Dermatology

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In an interview segment with Kirby, she described her views on the need for future research into povorcitinib for hidradenitis suppurativa patients, as well as her outlook on treatment.

In the interview, Kirby discussed recent trial data on povorcitinib indicating significant decreases in total abscess and inflammatory nodule count for hidradenitis suppurativa patients.

In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

In an interview with Maria Teresa García-Romero, MD, MPH, a discussion was held regarding the need for a morphea severity tool for pediatric patients.

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

Mental health outcomes for those with hidradenitis suppurativa who have had a previous surgery were explored in recent research.

New research explored associations between lesions resulting from Degos and diffuse cutaneous systemic sclerosis.

An interview segment with Alexa Kimball, MD, MPH, in which she describes further updates on 52 week trial data in the SUNRISE and SUNSHINE trials for HS.

A recent interview with Alexa Kimball, MD, MPH, regarding recent data from the SUNRISE and SUNSHINE studies on secukinumab for HS patients.

The treatment, developed by Pfizer, has been approved by the FDA for adult patients with atopic dermatitis.

In recent phase 2 trial data, a monoclonal antibody called vixarelimab showed strong results for prurigo nodularis treatment.

Research was conducted into the development of a tool for assessing morphea disease severity in pediatric patients.

A phase 2 trial published in NEJM describes the effects of the oral selective kappa opioid receptor agonist difelikefalin in patients with notalgia paresthetica—a condition with no FDA-approved therapies.

An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.

A list of the top stories covered this week in the dermatology field, with data on breakthroughs, new research, and advanced treatment options.

In recent research into alopecia areata treatments, selective JAK1 inhibition was tested as a means for restoring hair growth.

A recent research letter identified a correlation between mRNA vaccines for COVID-19 and cases of chronic spontaneous urticaria, although the connection requires further study.

In this recent study, mental health conditions associated with alopecia areata were assessed by the study’s investigators.

The latest HCPLive interview segment with Karan Lal, DO, discussing his views on what can go wrong during cosmetic procedures.

Shawn Kwatra, MD, and Sarina B. Elmariah, MD, PhD, share final pearls of wisdom for other physicians taking care of patients with prurigo nodularis (PN).

Experts in dermatology discuss unmet needs in prurigo nodularis (PN) and the importance of addressing those needs for disease management.

Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review exciting new therapies in the treatment landscape of PN.